Skip To Main Content
Marcellus Augustine on Muck Rack

Marcellus Augustine

As seen in: Nature, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Marcellus Augustine’s profile

Articles by Marcellus Augustine

Plasma signals of lung tumor promotion for molecular cancer prevention

|
By Tej Pandya, Maria Zagorulya, Michelle Leung, Marcellus Augustine, Lydia Y. Liu, Aino-Maija Leppä, Anthony Griffen, Oleg Blyuss, Chrysante S. Iliakis, Amalie Grenov, Kerstin Haase, Ulysse Baruchel, Tamara Klockner, Miriam Mugabo
| Cell Press Verified
Open in Who Shared Issue with article?

Subclonal immune evasion in non-small cell lung cancer

|
By Krijn K. Dijkstra, Roberto Vendramin, Despoina Karagianni, Maartje Witsen, Felipe Galvez-Cancino, Mark Hill Verified, Kane Foster, Mihaela Angelova, Robert Hynds, David Pearce, Carlos Martinez-Ruiz, James Black, Ariana Huebner, Oriol Pich, Andrew Rowan Verified, Marcellus Augustine, Clare Puttick, David Moore, Sadegh Saghafinia, Selvaraju Veeriah, Cristina Naceur-Lombardelli, Crispin T Hiley, Mariam Jamal-Hanjani, Nicholas McGranahan, Kevin Litchfield, James L. Reading, Benny Chain, Sergio A Quezada, Emile E. Voest, Charles Swanton, Vittorio Barbè, Lydia L. Liu, Joris van de Haar, Antonia Toncheva, Supreet Kaur Bola
| Cell Press Verified
Main text (Cancer Cell 43, 1833–1849; October 13, 2025) This paper identifies subclonal immune escape in non-small cell lung cancer using clonally resolved organoid-immune cell co-cultures. We, the authors of this publication, have identified an error in the code used to process the organoid RNA sequencing (RNA-seq) data for patient 1 in our study.
Open in Who Shared Issue with article?

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation

|
By Marcellus Augustine, Nuno Rocha Nené, Hongchang Fu, Christopher L. Pinder, Lorena Ligammari, Alexander Simpson, Irene Sanz-Fernández, Krupa Thakkar, Danwen Qian, Evelyn Fitzsimons, Benjamin S. Simpson, Roberto Vendramin, Andrea Castro, Samra Turajlic, Sergio A Quezada, Nicholas McGranahan, Chris Watkins, Charles Swanton, Kevin Litchfield, Heather Niederer
| Nature Verified
Abstract Immunotherapy has revolutionized cancer treatment, yet only a minority of individuals respond clinically, necessitating alternative strategies that can benefit these patients. Novel immuno-oncology targets may achieve this through bypassing resistance mechanisms to standard therapies. We introduce Mining Immunotherapy Drug tArgetS (MIDAS), a multimodal graph neural network system for immuno-oncology target discovery.
Open in Who Shared Issue with article?

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome

|
By Roberto Vendramin, Hongchang Fu, Shanila Fernandez Patel, Yue Zhao, Danwen Qian, Lorena Ligammari, Osnat Bartok, Polina Greenberg, Ronen Levy, Andrea Castro, Krupa Thakkar, Jun Murai, Wei-Ting Lu, Christopher C.T. Sng, Chen Weller, Gordon Beattie, Amandeep Bhamra, Roc Farriol-Duran, Despoina Karagianni, Krijn K. Dijkstra, Christopher L. Pinder, Benjamin Simpson, Gordon Cheung, Felipe Galvez-Cancino, Petra Vlckova, Silvia Surinova, Manuel Rodriguez-Justo, Mansi Shah, Nicholas McGranahan, Jeremy G. Carlton, Eva Grönroos, James L. Reading, Yardena Samuels, Charles Swanton, Sergio A Quezada, Kevin Litchfield, Marcellus Augustine
| Cell Press Verified
Keywords nonsense-mediated mRNA decay non-canonical neoantigens cryptic peptides cancer immunopeptidome SMG1 tumor immunogenicity cancer immunotherapy patient-derived fragments Introduction Effective anti-tumor immunity relies on the ability of T cells to detect cancer-associated peptides presented by the major histocompatibility complex (MHC) molecules and is shaped by both the quantity and quality of neoantigens.1,2 Among these, mutation-derived neoantigens (peptides derived from...
Open in Who Shared Issue with article?

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome

|
By Roberto Vendramin, Hongchang Fu, Shanila Fernandez Patel, Yue Zhao, Danwen Qian, Lorena Ligammari, Osnat Bartok, Polina Greenberg, Ronen Levy, Andrea Castro, Krupa Thakkar, Jun Murai, Wei-Ting Lu, Christopher C.T. Sng, Chen Weller, Gordon Beattie, Amandeep Bhamra, Roc Farriol-Duran, Despoina Karagianni, Marcellus Augustine, Krijn K. Dijkstra, Christopher L. Pinder, Benjamin Simpson, Gordon Cheung, Felipe Galvez-Cancino, Petra Vlckova, Silvia Surinova, Manuel Rodriguez-Justo, Mansi Shah, Nicholas McGranahan, Jeremy G. Carlton, Eva Grönroos, James L. Reading, Yardena Samuels, Charles Swanton, Sergio A Quezada, Kevin Litchfield
| Cell Press Verified
Keywords nonsense-mediated mRNA decay non-canonical neoantigens cryptic peptides cancer immunopeptidome SMG1 tumor immunogenicity cancer immunotherapy patient-derived fragments Introduction Effective anti-tumor immunity relies on the ability of T cells to detect cancer-associated peptides presented by the major histocompatibility complex (MHC) molecules and is shaped by both the quantity and quality of neoantigens.1,2 Among these, mutation-derived neoantigens (peptides derived from...
Open in Who Shared Issue with article?
Show More